ArticleThe American journal of pathology2003
Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant ischemia/reperfusion damage, acute rejection, and chronic nephropathy.
Article in The American journal of pathology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 88 citations in OpenAlex.
- Trial
- Value of plasmatic membrane attack complex as a marker of severity in acute kidney injury.BioMed research international · 2014Trial
- Novel interactions between the C5-C5aR1 Axis and IF1: Implications for kidney mitochondrial physiology and ischemia-reperfusion injury.Physiological reports · 2026Article
- Rationale for Targeting Complement to Mitigate Renal Transplant Ischemia-Reperfusion Injury.Journal of the American Society of Nephrology : JASN · 2026Review
- Article
- The Complement System in Kidney Transplantation.Cells · 2023Review
- An indium-111-labelled membrane-targeted peptide for cell tracking with radionuclide imaging.RSC chemical biology · 2023Article
- Ex vivo anchored PD-L1 functionally prevent in vivo renal allograft rejection.Bioengineering & translational medicine · 2022Article
- Inhibition of thrombin on endothelium enhances recruitment of regulatory T cells during IRI and when combined with adoptive Treg transfer, significantly protects against acute tissue injury and prolongs allograft survival.Frontiers in immunology · 2022Article
- Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2021Article
- Article
- Rationale for targeting complement in COVID-19.EMBO molecular medicine · 2020Review
- The Role of Complement in Organ Transplantation.Frontiers in immunology · 2019Review
- Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury.The Journal of clinical investigation · 2016Article
- What Is Direct Allorecognition?Current transplantation reports · 2016Review
- The Complement System and Antibody-Mediated Transplant Rejection.Journal of immunology (Baltimore, Md. : 1950) · 2015Review
- The role of the complement system in acute kidney injury.Seminars in nephrology · 2013Review
- Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts.Circulation · 2013Article
- The role of complement in the early immune response to transplantation.Nature reviews. Immunology · 2012Review
- Therapeutic regulation of complement in patients with renal disease - where is the promise?Clinical nephrology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complement activation during ischemia and reperfusion contributes to the development of tissue injury with severe negative impact on outcomes in transplantation. To counter the effect of complement, we present a strategy to deliver a novel complement regulator stabilized on cell surfaces within donor organs. The membrane-bound complement regulator is able to inhibit complement activation when the donor organ is revascularized and exposed to host-circulating complement. Application of this construct to donor kidneys protected transplanted tissues from ischemia/reperfusion injury and reduced the deposition of activated complement and histological signs of damage under conditions in which a nontargeted control construct was ineffective. Treatment of donor organs in this way improved graft performance in the short and long term. An analysis of the immune response in allograft recipients showed that reducing graft damage at the time of transplantation through complement regulation also modulated the alloresponse. Additionally, the results of perfusion studies with human kidneys demonstrated the feasibility of targeting endothelial and epithelial surfaces with this construct, to allow investigation in clinical transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.